Dr. Mellert is a Director within the Biodesix Development group. She has a background in molecular cancer biology and experience leading teams in the development and commercialization of blood-based diagnostic tests under CAP/CLIA and NYS CLEP. Dr. Mellert has played a leading role in the support of GeneStrat including the launch of EML4-ALK, ROS1 and RET fusion tests out of blood. She continues to focus her efforts on bringing relevant and actionable information to physicians in the academic and community setting. Dr. Mellert received her Ph.D from the University of Pennsylvania and post-doctoral training at the University of Colorado. She has received a number of awards including the American Cancer Society Post-doctoral fellowship.